66P Targeted treatment (TT) after immune checkpoint inhibitors (ICIs) in BRAF V600E mutated (BRAFm) and deficient mismatch repair or microsatellite instability high (dMMR/MSI-H) metastatic colorectal cancer (mCRC).
Saved in:
| Title: | 66P Targeted treatment (TT) after immune checkpoint inhibitors (ICIs) in BRAF V600E mutated (BRAFm) and deficient mismatch repair or microsatellite instability high (dMMR/MSI-H) metastatic colorectal cancer (mCRC). |
|---|---|
| Authors: | Ambrosini, M.1 (AUTHOR), Tougeron, D.2 (AUTHOR), Modest, D.P.3 (AUTHOR), Guimbaud, R.4 (AUTHOR), Kopetz, S.5 (AUTHOR), Decraecker, M.6 (AUTHOR), Sclafani, F.7 (AUTHOR), Coutzac, C.8 (AUTHOR), Lievre, A.9 (AUTHOR), Alouani, E.L.10 (AUTHOR), Marmorino, F.11 (AUTHOR), Pernot, S.12 (AUTHOR), Sinicrope, F.A.13 (AUTHOR), Elez Fernandez, M.E.14 (AUTHOR), Germani, M.M.11 (AUTHOR), Pietrantonio, F.15 (AUTHOR), Lonardi, S.16 (AUTHOR), Parent, P.17 (AUTHOR), Gallois, C.1 (AUTHOR), Taieb, J.1 (AUTHOR) |
| Source: | Annals of Oncology. 2024 Supplement 1, Vol. 35, pS32-S32. 1p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
